- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
CELG
Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
3 Big Stock Charts for Monday: American Airlines Group, Mylan and Celgene
The stock charts of CELG, AAL and MYL stock are going to start the new trading week out in a clear technical condition.
Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat
Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up Thursday on an earnings per share and revenue beat.
Why Is Bristol-Myers Near 52-Week Lows?
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock's acquisition of Celgene isn't the only reason.
Is Celgene Stock Still Worth Holding Onto in the Long Run?
Celgene and Bristol-Myers got the green light from shareholders to move forward on the deal. More upside awaits for CELG stock.
5 Top Stock Trades for Monday: Lyft, RH, Celgene, Wells Fargo
Restoration Hardware, Bristol-Myers, Celgene, Lyft's IPO and Wells Fargo are our top stock trades to watch for Monday.
Celgene News: Why CELG Stock Is Surging Today
Celgene news concerning the company's ongoing deal with Bristol-Myers Squibb (BMS) has CELG stock on the rise for Friday.
Friday’s Vital Data: Square, Southwest Airlines and Celgene
Options trading was buzzing in Southwest Airlines, Celgene, and Square on Thursday. Here are the metrics that matter moving forward.
5 Top Stock Trades for Friday: CELG, SQ, FIT, BOX
Bristol-Myers deal for Celgene is in doubt, while Box, Square, JD.com and Fitbit are moving on earnings. Here's are top stock trades for Friday.
Celgene Stock (CELG) Slides Lower on Opposition to Bristol-Meyers Deal
Celgene stock was on its way down Thursday following news that major investors are against a deal with Bristol-Meyers (BMY).
Friday’s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard
Options trading was buzzing in Bristol-Myers, Activision Blizzard and Intel hursday. Here are the metrics that matter moving forward.
Celgene vs. Gilead Stock: What’s the Better Biotech Buy?
Gilead stock has been stagnating, but there are other choices for investors. How about considering Celgene over GILD stock?
Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer?
Celgene shareholders who bought CELG stock at lows last year started 2019 on a bright note; Bristol-Myers is buying it for $74 billion.
5 Must-See Stock Charts for Tuesday, Including Roku
Roku soared, while the S&P 500, Twilio, Eli Lilly and Nvidia all perked up as well. Here are a few must-see stock charts for Tuesday.
Friday’s Vital Data: Apple, American Airlines and Bristol-Myers
Options trading was buzzing in Apple, American Airlines and Bristol-Myers Squibb on Thursday. Here are the metrics that matter moving forward.
3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
5 Must-See Stock Charts for Friday: Apple’s Fallout Hits Many
Apple, Celgene and Bristol-Myers made a lot of noise Thursday. Here are a must-see stock charts as a result.
Celgene Stock Surges on Bristol-Myers Mega Deal
Bristol-Myers is taking on the job of bringing Celgene's big pipeline of anti-cancer drugs to the market, and extracting the most value possible from them.
